Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis.
Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis.
复制标题
DOI：
10.1016/j.rdc.2022.08.005
复制
发表时间：
2023-02
期刊：
影响因子：
--
通讯作者：
B. Weber;K. Liao
中科院分区：
文献类型：
--
作者：
B. Weber;K. Liao
摘要/概要：与无这些疾病的患者相比，全身性自身免疫炎性关节炎与心血管（CV）风险增加相关，并且是发病率和死亡率的主要原因（1-5）。较新的生物药物修饰抗类风湿药物（bDMARD）和小分子药物改变了治疗模式，使疾病活动得到更严格的控制，在某些情况下，缓解。有证据表明，大多数bDMARD也可能降低心血管风险，尽管前瞻性干预数据仍然很少。此外，最近的研究结果引起了人们对针对特定途径的治疗的关注，这些途径可能会对心血管风险产生负面影响。这篇综述将涵盖类风湿性关节炎、银屑病关节炎和脊柱关节病的关键生物学通路。
Abstract/Synopsis:Systemic auto-immune inflammatory arthritides are associated with increased cardiovascular (CV) risk compared to those without these conditions, and is a leading cause of morbidity and mortality (1–5). Newer biologic drug modifying anti-rheumatoid drugs (bDMARD) and small molecules have transformed treatment paradigms enabling tighter control of disease activity and in some cases, remission. There is evidence to suggest that the majority of bDMARDs may also reduce cardiovascular risk, although prospective interventional data remains sparse. Additionally, recent results raise concern for treatments targeting specific pathways that may negatively affect cardiovascular risk. This review will cover key biologic pathways targeted in rheumatoid arthritis, psoriatic arthritis, and spondyloarthropathies.